A blood test being developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer’s disease more quickly has been awarded breakthrough status by the FDA, which could help it ...
Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...
Impairment in both an odor identification test and global cognition is comparable to positron emission tomography (PET) with 11C-Pittsburgh compound B (11C-PiB) for predicting cognitive decline and ...